- Home
- CCCC vs KF Comparison
CCCC vs KF Comparison
Compare CCCC & KF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- KF
- Stock Information
- Founded
- CCCC 2015
- KF 1984
- Country
- CCCC United States
- KF United States
- Employees
- CCCC N/A
- KF N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- KF Investment Managers
- Sector
- CCCC Health Care
- KF Finance
- Exchange
- CCCC Nasdaq
- KF Nasdaq
- Market Cap
- CCCC 104.4M
- KF 90.9M
- IPO Year
- CCCC 2020
- KF N/A
- Fundamental
- Price
- CCCC $2.26
- KF $27.70
- Analyst Decision
- CCCC Buy
- KF
- Analyst Count
- CCCC 3
- KF 0
- Target Price
- CCCC $12.00
- KF N/A
- AVG Volume (30 Days)
- CCCC 2.0M
- KF 18.4K
- Earning Date
- CCCC 08-04-2025
- KF 01-01-0001
- Dividend Yield
- CCCC N/A
- KF N/A
- EPS Growth
- CCCC N/A
- KF N/A
- EPS
- CCCC N/A
- KF N/A
- Revenue
- CCCC $39,783,000.00
- KF N/A
- Revenue This Year
- CCCC N/A
- KF N/A
- Revenue Next Year
- CCCC N/A
- KF N/A
- P/E Ratio
- CCCC N/A
- KF N/A
- Revenue Growth
- CCCC 98.56
- KF N/A
- 52 Week Low
- CCCC $1.09
- KF $18.30
- 52 Week High
- CCCC $7.36
- KF $25.56
- Technical
- Relative Strength Index (RSI)
- CCCC 60.73
- KF 65.22
- Support Level
- CCCC $2.15
- KF $27.16
- Resistance Level
- CCCC $2.53
- KF $27.96
- Average True Range (ATR)
- CCCC 0.28
- KF 0.31
- MACD
- CCCC 0.02
- KF -0.11
- Stochastic Oscillator
- CCCC 62.13
- KF 80.74
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.